Dr Reddy’s may launch 3 new drugs in the US and to issue bonus debentures worth Rs 520 crore

10 Mar 2011 Evaluate

Dr Reddy’s Laboratories may launch three new drugs in the US market next fiscal after the settlement of disputes with foreign players over the rights to two of them and a favourable court ruling in a third case.Dr Reddy’s may launch Rivastigmine ($132m), an anti-mild-to-moderate Alzheimer’s drug, Desloratadine, ($229 mn) used to treat allergies and Pseudoephedrine, a nasal/sinus decongestant.

In 2008, the company entered into a settlement agreement with Novartis Pharma that involves a stipulation of dismissal of lawsuits filed in the United States relating to Rivastigmine capsules sold under the trade name Exelon.Dr Reddy’s inked agreements in 2009 with Schering and Sepracor of the USA, which will allow the Indian drug-maker to manufacture and market generic versions of Desloratadine, starting 2012. Similarly, Dr Reddy’s got a shot in the arm after the US District Court of New Jersey recently cleared decks for the launch of the generic version of Allegra-D 24 in US. The revenues from generic sales in North America stood at $301 million in the last fiscal and $287 million so far this year.

Dr Reddy's Laboratories will issue bonus debentures to its shareholders worth up to Rs 520 crorecrackcrack

Dr. Reddys Lab Share Price

1342.45 16.45 (1.24%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.